Michael Sitzman

For more than 30 years, Michael has represented biotechnology and pharmaceutical companies in high stakes patent litigation and other intellectual property matters. Michael has litigated cases involving recombinant DNA, CAR-T technology, glycobiology, antisense technology, protein synthesis and regulation and immunological markers for such companies as Allergan, AbbVie, Alza, Depomed, Genentech, Gilead, Janssen Pharmaceuticals, Medicis, Merck Serono, Novo Nordisk and Ultragenyx.

Michael represents brand-name and innovator pharmaceutical companies in biologic and drug patent litigation, including ANDA litigation. Michael was one of the chief architects of the strategy for Novo Nordisk that culminated in the Supreme Court's first substantive review of the Hatch-Waxman Act.

Before becoming an attorney, Michael worked at the UC Davis Plant Growth Laboratory and Biogenex, combining the fields of immunology, histology and general chemistry.
Michael regularly appears pro hac vice in the district courts of New Jersey, Delaware, Maryland and the Southern District of New York. He is a Global Fellow of the Federal Circuit Bar Association and speaks regularly at PLI and ACI conferences on issues of biotechnology and pharmaceutical patent law.
Speaking In
4:15 PM - 5:15 PM
Tuesday, June 6
An increasingly vocal group of critics complain that life-sciences patents are holding up…